Abstracts tagged "Spondyloarthropathies"

Abstract Number: 1612 • ACR Convergence 2022
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁴, Christopher Ritchlin⁵, Cheryl F Rosen⁴, Richard Cook² and Dafna Gladman⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
Abstract Number: 0416 • ACR Convergence 2022
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Casper Webers¹, Augusta Ortolan², Alexandre Sepriano³, Louise Falzon⁴, Xenofon Baraliakos⁵, Robert Landewé⁶, Sofia Ramiro⁷, Désirée van der Heijde⁸ and Elena Nikiphorou⁹, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²University of Padova/Leiden University Medical Center, Padova, Italy, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁹Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Since the 2016 update of the management recommendations for axial spondyloarthritis (axSpA), new evidence has emerged on the efficacy and safety of biological disease-modifying…
Abstract Number: 1035 • ACR Convergence 2022
Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
Philip J Mease¹, William Tillett², Sarah Ohrndorf³, Michelle Perate⁴, Mary Medysky⁵, Miriam Zimmermann⁶, May Shawi⁷, Emmanouil Rampakakis⁸, Paul Bird⁹, Alen Zabotti¹⁰, Atul Deodhar¹¹ and Dafna Gladman¹², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Seattle, WA, ⁶Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹University of New South Wales, Sydney, Australia, ¹⁰Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ¹²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Evidence on the efficacy of advanced therapies for axial involvement in PsA (axPsA) is scarce, largely due to the lack of a widely accepted…
Abstract Number: 1768 • ACR Convergence 2022
Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
Sanjana Tarannum¹, Jessica Widdifield¹, C. Fangyun Wang², Sindhu R. Johnson³, Paula Rochon¹ and Lihi Eder⁴, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Delayed diagnosis of inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), is associated with joint damage and disability.…
Abstract Number: 0796 • ACR Convergence 2022
SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
Carla Goncalves Schahin Saad¹, Matheus SR Silva², PERCIVAL SAMPAIO-BARROS¹, Julio Moraes³, Claudia G Schainberg², Celio Roberto goncalves¹, Andrea Shimabuco¹, Nadia Aikawa¹, Emily Figueiredo Neves Yuki¹, Sandra Gofinet Pasoto⁴, Leonard VK Kupa², Renato K Aoyama², Carlo Araujo¹, Clovis A. Silva⁵, ana Medeiros⁶ and Eloisa Silva Dutra de Oliveira Bonfa⁴, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, ³Faculdade de Medicina da Universidade de Sao Paulo, Jundiai, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil
Background/Purpose: Spondyloarthritis(SpA) patients are exposed to a variety of immunosuppressors capable of reduce humoral responses to vaccination. In context of the SARS-CoV-2 pandemic, assessment of…
Abstract Number: 1037 • ACR Convergence 2022
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies
Xenofon Baraliakos¹, Dafna Gladman², Soumya Chakravarty³, Cinty Gong⁴, May Shawi⁵, Emmanouil Rampakakis⁶, Kishimoto Mitsumasa⁷, Enrique R Soriano⁸ and Philip J Mease⁹, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only…
Abstract Number: 2108 • ACR Convergence 2022
Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA
Stefan Siebert¹, Georg Schett², Siba P. Raychaudhuri³, Monica Guma⁴, Warner Chen⁵, Sheng Gao⁵, Soumya Chakravarty⁶, May Shawi⁷ and Proton Rahman⁸, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Universitätsklinikum Erlangen, Erlangen, Germany, ³Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Memorial University, St. John's, NL, Canada
Background/Purpose: The IL-23p19 inhibitor guselkumab has shown robust efficacy vs placebo (PBO) in the phase 3 DISCOVER-1 and DISCOVER-2 studies of adults with active PsA,1,2…
Abstract Number: 0382 • ACR Convergence 2021
Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
Carolina Tornero¹, Victoria Navarro-Compán², raquel almodovar³, Cristina fernández-Carballido⁴, Azucena Hernández⁵, Beatriz Joven-Ibáñez⁶, Xavier Juanola⁷, M.Lourdes Ladehesa-Pineda⁸, José Ramón maneiro⁹, Antoni Juan Mas¹⁰, carlos Montilla¹¹, Manuel J Moreno¹², Mireia moreno¹³, José A. pinto¹⁴, juan Carlos Quevedo¹⁵, José Rosas¹⁶, Teresa Ruiz¹⁷, Jesús Sanz¹⁸ and Eugenio De Miguel¹⁹, ¹University Hospital La Paz, Madrid, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Hospital Universitario Fundación de Alcorcón, Madrid, Spain, ⁴H. San Juan, Alicante, Alicante, Spain, ⁵Hospital Virgen de la Salud, Toledo, Spain, ⁶University Hospital 12 de Octubre, Madrid, Spain, ⁷Hospital Universitari de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario Reina Sofía, Córdoba, Spain, ⁹Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain, ¹⁰Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ¹³Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain, ¹⁴Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ¹⁵Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, ¹⁷Hospital de Sierrallana, Servicio de Reumatología, Torrelavega, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁹Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Esperanza was a multicenter national health program developed to facilitate an early diagnosis of patients with Spondyloarthritis (SpA) in Spain. The main objective of…
Abstract Number: 1322 • ACR Convergence 2021
Body Mass Index (BMI) Underestimates Obesity in Females with Axial Spondyloarthropathy
Sinead Maguire¹, Wilson Fiona², Phil Gallagher³ and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland
Background/Purpose: Worldwide prevalence of obesity has been steadily increasing, despite public health campaigns to raise awareness. In axial spondyloarthropathy (axSpA) obesity has been shown to…
Abstract Number: 0383 • ACR Convergence 2021
Differences Between Male vs. Female Presenting with Back Pain in an Integrated Delivery System
Aniket Kawatkar¹, Esther Yi², Erika Estrada¹, Jose Pio¹, Cecilia Portugal¹, David Yi¹ and Steve Lee³, ¹Kaiser Permanente Southern California, Pasadena, CA, ²Novartis Pharmaceuticals Corporation, Weehawken, NJ, ³Southern California Permanente Medical Group, Fontana, CA
Background/Purpose: Back pain exerts significant economic burden and in its inflammatory form is the main clinical symptom of axial spondylarthritis. We evaluated differences in patient…
Abstract Number: 1550 • ACR Convergence 2021
Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases
Anna Carbone, Gentiana Vukatana, Enrica Vandelli, Marica Trevisani, Elisa Rossi, Rita Mulè and Marco Fusconi, Rheumatology Unit, Azienda Ospedaliero-Universitaria Bologna, Bologna, Italy
Background/Purpose: There is increasing interest in the safety of COVID-19 vaccination in patients with underlying chronic conditions. We investigated the rates of side effects and/or…
Abstract Number: 0450 • ACR Convergence 2021
Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis
Mark Hwang¹, Minjae Lee², Lianne Gensler³, Matthew Brown⁴, Amirali Tahanan⁵, Mohammad Rahbar⁶, Theresa Hunter⁷, Mingyan Shan⁸, Mariko Ishimori⁹, John Reveille¹⁰, Michael Weisman¹¹ and Thomas Learch¹², ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²UT Southwestern, Dallas, TX, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴King's College London, London, United Kingdom, ⁵McGovern Medical School, Houston, TX, ⁶Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, ⁷Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Cedars-Sinai Health System, Los Angeles, CA, ¹⁰Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ¹¹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹²Cedars-Sinai, Los Angeles, CA
Background/Purpose: Little is known about the natural history of spinal disease in Ankylosing Spondylitis (AS). Our objective was to identify distinct patterns of change in…
Abstract Number: 1786 • ACR Convergence 2021
Association of the Improvement of Synovitis and Enthesitis with Quality of Life/Patient Reported Outcomes in Patients with PsA Treated with Ixekizumab
Lars Erik Kristensen¹, Dennis McGonagle², Martin Rudwaleit³, Hideto Kameda⁴, Thorsten Holzkaemper⁵, Celine El Baou⁶ and Josef Smolen⁷, ¹Bispebjerg-Frederiksberg Hospital, Copenhagen,, Denmark, ²University of Leeds, Leeds, United Kingdom, ³Bielefeld University, Rheumatology, Klinikum Bielefeld, Berlin, Germany, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Eli Lilly and Company, Bad Homburg, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Medical University of Vienna, Vienna, Austria
Background/Purpose: PsA is an inflammatory rheumatic disease with manifestations including synovitis and enthesitis. During extensive study programs, IXE has shown a treatment effect across domains…
Abstract Number: 0451 • ACR Convergence 2021
Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
Murat Torgutalp¹, Valeria Rios Rodriguez¹, Maryna Verba², Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Hildrun Haibel³, Martin Rudwaleit⁴, Joachim Sieper³ and Denis Poddubnyy⁵, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁵Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Observational cohort studies have shown that there is low, but still detectable progression level in radiographic sacroiliitis, which might also have an impact on…
Abstract Number: 1829 • ACR Convergence 2021
Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
Rita Torres¹, Santiago Manica² and Fernando Santos², ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ²Hospital Egas Moniz, Lisboa, Portugal
Background/Purpose: Enthesitis is a recognized as a hallmark of spondyloarthrtis (SpA), including psoriatic arthritis (PsA). However, it is an underestimated disease domain in both in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].